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High-Intensity Aerobic Exercise 
Improves Both Hepatic Fat Content 
and Stiffness in Sedentary Obese 
Men with Nonalcoholic Fatty Liver 
Disease
Sechang Oh1,2,3,*, Rina So3,4,*, Takashi Shida5, Tomoaki Matsuo4, Bokun Kim6, 
Kentaro Akiyama3,5, Tomonori Isobe2, Yoshikazu Okamoto2, Kiyoji Tanaka7 & Junichi Shoda1,2
We compared the effects of 12-week programs of resistance training (RT), high-intensity interval 
aerobic training (HIAT), and moderate-intensity continuous aerobic training (MICT). The primary goal 
was to evaluate the therapeutic effects of the exercise modalities for the management of nonalcoholic 
fatty liver disease (NAFLD). A total of 61 sedentary obese men with NAFLD were randomized into one 
of the following exercise regimens (RT, HIAT, or MICT). Hepatic fat content was decreased to a similar 
extent in the RT, HIAT, and MICT groups (−14.3% vs. −13.7% vs. −14.3%) without significant changes 
in weight and visceral fat. The gene expression levels of fatty acid synthesis were significantly decreased 
in the subjects’ monocytes. Hepatic stiffness was decreased only in the HIAT group (−16.8%). The 
stiffness change was associated with restored Kupffer cell phagocytic function (+17.8%) and decreased 
levels of inflammation such as leptin (−13.2%) and ferritin (−14.1%). RT, HIAT, and MICT were equally 
effective in reducing hepatic fat content, but only HIAT was effective in improving hepatic stiffness 
and restoring Kupffer cell function. These benefits appeared to be independent of detectable weight 
and visceral fat reductions; the benefits were acquired through the modulation of in vivo fatty acid 
metabolism and obesity-related inflammatory conditions.
Due to westernization of dietary habit and chronically decreased physical activity, the number of obese subjects 
is currently growing steadily. Visceral fat accumulation accompanied with obesity is an important disease back-
ground of nonalcoholic fatty liver disease (NAFLD)1,2. Since increased risks of cardiovascular events3 and diabetes 
mellitus have been observed in patients with NAFLD4, NAFLD should be regarded not only as a hepatic disease 
but also as a systemic disease.
Only dietary and exercise therapies have demonstrated effectiveness for the prevention of the onset and pro-
gression of NAFLD. Exercise is beneficial for reducing visceral fat and is reportedly effective in improving patho-
logical conditions of NAFLD including fat accumulation, inflammation, and fibrosis5,6. The improvement and 
inhibition of the progression of these hepatic conditions by exercise can have a significant impact in the manage-
ment of NAFLD.
Cross-sectional studies have shown that the hepatic pathological conditions of NAFLD are inversely cor-
related with the levels of physical activity7 and fitness8,9, which strongly support the direct benefit of exercise 
to the liver. Since the disease conditions of obesity are closely related to NAFLD10, management of NAFLD by 
dietary and exercise therapies is drawing more interest. Long-term studies are being conducted at many medical 
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institutions to investigate the effect of exercise on fat accumulation in the liver and hepatic dysfunction and to 
reveal the effect of exercise separately from that of dietary therapy6,11. However, the evidence regarding the bene-
fits of exercise to NAFLD is still insufficient.
A systematic review and meta-analysis were recently conducted to evaluate the efficacy of exercise interven-
tions for the improvement in hepatic fat accumulation in NAFLD subjects12. The results indicated the benefits of 
exercise in decreasing hepatic fat accumulation even in cases of little or no weight reduction. Notably, reduced fat 
accumulation in the liver was observed with a level of exercise lower than the level that is currently recommended 
for the management of obesity13.
We reported that exercise alone improved hepatic dysfunction, even though exercise resulted in smaller 
changes in weight and visceral fat reduction than the results achieved with dietary restriction therapy. In addition, 
we conducted a study to determine the best exercise intensity and duration to reduce hepatic fat accumulation. 
Our results demonstrated that 250 min or more of moderate to vigorous physical activity each week had the 
greatest effect on hepatic fat reduction and its underlying pathophysiology, independent of weight reduction14.
Recently, the ameliorating effect of resistance exercise on hepatic fat accumulation in NAFLD has been 
observed15,16. Resistance exercise has only a small effect on weight reduction and body composition. However, 
resistance exercise has been demonstrated to increase basal energy expenditure by increasing muscle volume17, 
and improve insulin sensitivity18,19, a concurrent disease condition of obesity.
In addition to conventional exercise modalities, high-intensity interval aerobic training (HIAT) has recently 
been introduced as a new exercise therapy alternative20. In HIAT, short duration, high-intensity aerobic exercise 
and recovery time with low-load aerobic exercise are alternately repeated20. HIAT can be completed in 13 min. 
HIAT is thought to be the most effective form of exercise for subjects who do not have much time. The benefits of 
HIAT on cardiovascular disease21 and metabolic syndrome22 have also been reported.
We sought to establish evidence for the most appropriate modality, intensity, time, and duration of exercise for 
the management of NAFLD. Therefore, in this study, we conducted a randomized controlled trial (RCT) to com-
pare the effects of 12 weeks of resistance training (RT), HIAT, and moderate-intensity continuous aerobic training 
(MICT) in obese men with NAFLD. By analyzing the participants’ baseline and follow-up clinical measurements, 
we comparatively investigated the effects of the different exercise modalities on NAFLD.
Methods
Ethical approval. These clinical trials were approved by the Institutional Review Board of University of 
Tsukuba Hospital (ID: H25–156) and retrospectively registered with the University Hospital Medical Information 
Network Clinical Trials Registry (UMIN-CTR ID: UMIN000022901). All the procedures were carried out in 
accordance with the principles of the Declaration of Helsinki. We fully explained the purpose and design of the 
study to all the participants, and each participant signed an informed consent document.
Study Design. The workflow of enrollment to the program and exclusion criteria is provided in Fig. 1.
The participant recruitment, 12-week study intervention, and clinical tests were all performed at University 
of Tsukuba Hospital (Ibaraki, Japan) in 2013. Out of the initial 67 male applicants, 61 obese23 sedentary adult 
men with NAFLD were enrolled according to the study criteria. Obese adult men with no exercise habits (≤ 1 
session per week and ≤ 30 min per session) over the past year were included. Also, subjects with adverse medical 
Figure 1. Flowchart showing the study process. RT, resistance training; HIAT, high intensity aerobic training; 
MICT, moderate intensity continuous training.
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problems (all applicants undertook a medical interview and resting electrocardiogram test by a medical doctor) 
and who declined to participate in the current protocol were excluded. The diagnostic criteria of NAFLD were 
established by the diagnostic guidelines for NAFLD in the Asia-Pacific region24.
We conducted a prospective, single blind RCT for this study. After obtaining the baseline measurements, 
the 61 eligible subjects were assigned in a 1:1:1 ratio to one of the three intervention groups by a computer-
ized method (EXCEL 2010; Microsoft Corp, Redmond, USA) using block randomization with stratification on 
age and VO2Max. A research assistant who had no interaction with the subjects generated the random allocation 
sequence and enrolled the subjects. Out of the 61 subjects who were assigned to the exercise training programs 
consisting of 12 weeks, 3 times/week from August to December 2013, a total of 52 subjects (RT [n = 19] vs. HIAT 
[n = 20] vs. MICT [n = 13]) completed the study.
One Repetition Maximum (1-RM) Strength and Cardiorespiratory Capacity Test. The subjects 
in the RT group were given a 1-RM strength test. After a learning phase, the subjects performed 3 series of 12 
repetitions at a relatively light load as a warm-up. The warm-up was followed by a gradually increasing load until 
they achieved the 1-RM strength within 5 attempts with 1 min of recovery between series. We conducted the tests 
taking into consideration assisting the recovery and reducing the influence of fatigue. The tests were alternated 
between the upper and lower muscles.
The VO2Max test in the aerobics groups (HIAT and MICT) was performed on a graded direct cycling ergom-
eter [75XL, Konami, Tokyo, Japan] at weeks 0, 4, 8, and 12. Following a 2-minute warm-up at 30 watts, the 
workload increased every minute by 15 watts until volitional exhaustion. During the test, ventilation and gas 
exchanges were measured using an open-circuit computerized indirect calorimeter [AE-310S, Minato Medical 
Science, Osaka, Japan]. Heart rate at rest and during the test was supervised using an electrocardiogram monitor 
[DynaScope, Fukuda Denshi, Tokyo, Japan].
Training Programs. All subjects performed their assigned training program three times per week on 
nonconsecutive days for 12 weeks. During the study period, all of the subjects were asked not to perform the 
trial-specific exercise activities outside of the training program. Also, we asked each subject to not change any-
thing about their lifestyle and diet for 12 weeks.
The RT program referred to the ACSM 2009 position paper on “Progression Models in Resistance Training 
for Healthy Adults”25. The program consisted of 1) sit-ups, 2) leg presses, 3) leg extensions, 4) leg curls, 5) chest 
presses, 6) seated rows, and 7) pull-downs (Selection MED, Technogym, Cesena, Italy). The amount of load lifted 
was updated according to the results of the monthly direct 1-RM strength test. The total energy expenditure for 
the RT program was estimated to be about 180 kcal in our preliminary experiment. These values are similar with 
HIAT.
The detailed descriptions of the aerobics training (HIAT and MICT) regimens have been published else-
where20,26. Briefly, the HIAT consisted of three sets of 3-min cycling sessions at 80~85% VO2Max with a 2-min 
active rest at 50% VO2Max between sets (13 min, 180 kcal), and the MICT consisted of 40 min. of cycling at 60~65% 
VO2Max (40 min, 360 kcal). The exercise intensity was recalculated and updated following the monthly VO2Max 
measurements recording.
Daily Energy Intake. At baseline and at week 12, daily energy intake was estimated using both three-day 
and weight dietary records. The study subjects photographed and recorded the name and amount of every food 
item they ate. A dietician analyzed the dietary data using commercially available computer software [Eiyoukun 
version 6.0, Kenpakusya, Tokyo, Japan].
Anthropometry and Body Adiposity. Body weight was measured to the nearest 0.05 kg using a 
digital scale [WB-150, TANITA, Tokyo, Japan], and height was measured once to the nearest 0.1 cm using a 
wall-mounted stadiometer [YG-200, Yagami, Nagoya, Japan]. BMI was calculated as the weight divided by height 
squared (kg/m2). The study participants’ body composition was evaluated by dual-energy x-ray absorptiometry 
using a total body scanner [QDR 4500, Hologic Inc, Bedford, USA]. Their abdominal distribution was deter-
mined using magnetic resonance imaging [Achieva, Philips Electronics Japan Ltd, Tokyo, Japan], according to a 
previously described protocol27. Individual’s adipose tissue volume was calculated by multiplying the subcutane-
ous adipose tissue (SAT) and visceral adipose tissue (VAT) areas at the umbilicus level.
Hepatic Stiffness and Steatosis. Hepatic stiffness was assessed using transient elastography 
[FibroScan502®, Echosens, Paris, France] with the 3.5-MHz standard probe by a clinical gastroenterologist. The 
principles and examination procedures for such an assessment have been previously published28.
Hepatic fat content was determined using a controlled attenuation parameter (CAP) designed to measure the 
liver ultrasonic attenuation at 3.5 MHz using signals acquired with FibroScan502®. More detailed descriptions of 
the CAP have also been previously published29. Moreover, intrahepatic fat accumulation was determined by pro-
ton magnetic resonance spectroscopy [Achieva, Philips Electronics Japan Ltd, Tokyo, Japan] using a previously 
described protocol30.
Contrast Enhanced Ultrasonography (CEUS) of Liver. The CEUS liver parenchymal phase was used to 
determine the phagocytic capacity of Kupffer cells31. The detailed protocol for imaging the liver through contrast 
ultrasonography has been published elsewhere32. This time, we applied this protocol with some modification for 
the current CEUS measurements. Briefly, sonazoid used as a contrast agent was diluted to 0.1 mL/1200 g/body 
weight and injected into the vein of the subjects. A clinical gastroenterologist scanned the liver of the subjects 
using 1-second intermittent transmission scans at 40 min using ultrasonography [Aplio 400, Toshiba medical, 
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Tokyo, Japan]. The fluorescent ROI [intensity in the region of interest] was calculated using the equipment soft-
ware Advanced Dynamic Flow [Toshiba medical, Tokyo, Japan].
Blood Analysis. The level of fasting plasma glucose (FPG) was determined by the hexokinase-G-6-PDH 
method; fasting plasma insulin (FPI) by the chemiluminescent immunoassay method; aspartate aminotrans-
ferase (AST), alanine aminotransferase (ALT), and gamma glutamyl transpeptidase (γ GT) by the Japan 
Society of Clinical Chemistry transferable method; triglyceride; and free fatty acids (FFAs) by the enzymatic 
method. We calculated surrogate markers for insulin resistance (HOMA-IR)33 and for the NAFLD fibrosis score 
(NAFLD-FS)34. Commercial ELISA and ECL assay kits were used to determine serum levels of thiobarbituric 
acid reactive substances (TBARS) [Cayman Chemical, Ann Arbor, USA], tumor necrosis factor alpha (TNF-α ), 
interleukin-6 (IL-6), fibroblast growth factor-21 and leptin [R&D systems, Minneapolis, USA], total adiponec-
tin [Sekisui Medical, Tokyo, Japan], M30 apoptosense [Pavia, Bromma, Sweden], Selenoprotein P (SEPP1) and 
Myostatin (MSTN) [Cusabio biotech, Wuhan, China], Fetuin A [BioVendor Laboratory Medicine, Modreci, 
Czech Republic], WFA+ -Mac-2 binding protein (WFA+ -Mac M2BP) [Immuno-Biological Lab, Kunma, Japan]. 
Serum lipopolysaccharide (LPS) concentration was determined using the Limulus amoebocyte lysate assay kit 
[Associates of Cape Cod, East Falmouth, USA].
Quantitative Real-Time PCR analysis. Gene levels in peripheral blood mononuclear cells (PBMCs) are 
known as a good model to reflect physiological changes in the liver35, since liver and PBMCs originate evolution-
arily from the same body compartment36 PBMCs were isolated from whole blood using LSM density gradients 
[MP Biomedical, Santa Ana, USA]. The mRNA levels in the PBMCs were analyzed by real-time quantitative 
PCR using recently detailed methodology14. The primers (Fasmac, Tokyo, Japan) used in this study are shown in 
Table 1.
Statistical Analysis. Descriptive values were expressed as the means ± standard error (SE) and as per-
centages. For the analysis of categorical parameters, the chi-squared test or Fisher exact test was performed. To 
examine the differences among the groups at the baseline we used the one-way analysis of variance (ANOVA) 
test. Paired t tests were performed to test the significance of changes in clinical parameters within the groups. We 
also compared parameters among the groups that changed from the baseline to the 12th week using either the 
one-way ANOVA test or the analysis of covariance (ANCOVA) test with adjustments for the respective baseline 
values. The data were analyzed using SPSS version 23.0 for Windows package [IBM, Chicago, USA]. The level of 
statistical significance was set at P < 0.05.
Results
Baseline Characteristic. There were no statistically significant differences in the subjects’ characteristics 
and use of medications among the 3 groups (Table 2). The mean energy intake, anthropometric values (Table 3), 
and the hepatic steatosis and liver fibrosis marker levels (Fig. 2) were not significantly different among the groups. 
However, there were statistical differences in the 6 baseline serum values of LogAST (P < 0.05), ALT (P < 0.05), 
LogFPG (P < 0.01), HOMA-IR (P < 0.05), LogM30 (P < 0.01) and SEPP (P < 0.05) among the groups (Table 4). The 
gene expression levels (Table 5) were not significantly different among the 3 groups.
Intervention Adherence. Table 3 shows the results of energy intake for each group during the study period. 
According to the 3-d food-intake records, the 3 groups showed no significant changes in their energy intake 
values at week 12. The attendance rates were 89.5% in the RT group, 92.1% in the HIAT group, and 92.1% in the 
MICT group. The differences in attendance were not statistically significant (data not shown).
Body Weight and Cardiovascular Capacity. There were no significant changes in weight at week 12 in 
any of the groups, and the magnitude of the changes in weight were not significantly different among the groups 
Gene name Forward Reverse
GAPDH 5′ -AGGTGAAGGTCGGAGTCA-3′ 5′ -GGTCATTGATGGCAACAA-3′ 
SREBP1c 5′ -ATACCACCAGCGTCTACC-3′ 5′ -CACCAACAGCCCATTGAG-3′ 
ACC 5′ -ATGTCTGGCTTGCACCTAGTA-3′ 5′ -CCCCAAAGCGAGTAACAAATTCT-3′ 
CPT1 5′ -CTGTGCGCCCCTTGTTGGATG-3′ 5′ -GGGCTGCCTGCACGTCTGTATT-3′ 
ACO 5′ -AATCGGGACCCATAAGCCTTT-3′ 5′ -GGGAATACGATGGTTGTCCATTT-3′ 
CD11b 5′ -GAGTCCAACGCTAATGTCAAGG-3′ 5′ -CCCGTAGAGAACAGCATCACAC-3′ 
CD14 5′ -GAGTGTGCTTGGGCAATGCT-3′ 5′ -ATGCTGACACGGTCAAGGCT-3′ 
CD68 5′ -ATGATGAGAGGCAGCAAGATGG-3′ 5′ -GCTACATGGCGGTGGAGTACAA-3′ 
TLR4 5′ -CTAAACCAGCCAGACCTTG-3′ 5′ -ACCTGTCCCTGAACCCTAT-3′ 
HO1 5′ - CCAGGCAGAGAATGCTGAGT-3′ 5′ -GTAGACAGGGGCGAAGACTG-3′ 
NQO1 5′ -CTGATCGTACTGGCTCACTC-3′ 5′ -AACAGACTCGGCAGGATAC-3′ 
Table 1.  Primers Used for Quantitative Real-Time PCR. Abbreviations: GAPDH, glyceraldehyde 
3-phosphate dehydrogenase; SREBP1c, sterol regulatory element-binding protein 1c; ACC, acetyl-CoA 
carboxylase; CPT1, carnitine palmitoyltransferase I; ACO, acyl CoA oxidase; CD, cluster of differentiation; TLR, 
toll-like receptor; HO1, heme oxygenase 1; NQO1, NADH quinone oxidoreductase.
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(Table 3). The subjects’ VO2max was increased in all 3 groups (RT + 8.6%, HIAT + 21.6%, MICT + 16.1%) when 
the baseline results were compared to the week 12 results. A comparison among the 3 groups revealed that the 
changes were not statistically significant (data not shown).
Body Adiposity. The subjects’ fat mass was reduced in the RT and MICT groups, and lean mass was increased 
in the RT and HIAT groups when the baseline results were compared to the week 12 results (Table 3). However, 
the 2 measured values for abdominal distribution were not significantly changed at week 12. When an intergroup 
comparison was made, the magnitude of the change in these values was not significantly different.
Blood Test. Of the 11 values in biochemical values that were analyzed in this study (Table 4), three values 
(Logγ -GTP, FFAs and LPS) in the RT group (P < 0.05), two values (Logγ -GTP and Ferritin) in the HIAT group 
(P < 0.05), and four values (ALT, Logγ -GTP, FFAs and LPS) in the MICT group (P < 0.05) were significantly 
changed at week 12. The comparison among the groups revealed that the magnitude of the changes in all the 
values were not statistically significant. With regard to the markers associated with liver fibrosis, WFA+ -M2BP 
(Fig. 3B), there was no significant change in these values in any of the training groups at 12 weeks. Also, when an 
intergroup comparison was made, the magnitude of the changes in the WFA+ -M2BP values among the groups 
was not significantly different. For the adipokine, myokine and hepatokine analysis (Fig. 2), the RT group (− 
14.3%) and the HIAT group (− 13.2%) showed significantly decreased levels of leptin at week 12 (P < 0.05).
Hepatic Steatosis. The subjects’ hepatic fat content, as assessed by CAP, was reduced in all 3 groups (RT − 
14.3%, HIAT − 13.7%, MICT − 14.3%), when the baseline results were compared to the week 12 results (P < 0.05). 
However, a reduction in the intrahepatic fat content by MRS was only detected in the RT group (− 47.2%) and 
the HIAT group (− 16.6%) at week 12 (P < 0.05); the MICT group did not demonstrate any significant change in 
that value. A comparison among the 3 groups revealed that the changes were not statistically significant (Fig. 3A).
Liver Stiffness and Associated Markers. Figure 3(B) shows the results of changes in the hepatic stiffness 
assessed using transient elastography, NAFLD-FS as a surrogate marker, WFA+ -M2BP as a blood marker for 
hepatic stiffness, and the Kupffer phase assessed by contrast ultrasonography, for each group during the study 
period. In the HIAT group, significant improvements were observed in hepatic stiffness by − 16.8% and in the 
Kupffer phase by + 17.8% (P < 0.05). However, the other groups did not demonstrate significant changes. When 
an intergroup comparison was made, the magnitude of change in hepatic stiffness was greater in the HIAT group 
than in the MICT group (P < 0.01).
Expression Levels in the PBMCs. Table 5 shows the changes in the expression levels in the PBMC of the 
five fat metabolism-related genes (fatty acid synthesis: LogSREBP1c [sterol regulatory element-binding protein 1c], 
LogACC [acetyl-CoA carboxylase]; fatty acid degradation: LogCPT-1 [carnitine palmitoyltransferase-1], LogACO 
[acyl-CoA oxidase], five macrophage specific genes (LogCD11b [cluster of differentiation 11b], LogCD14 [cluster of 
differentiation 14], LogCD68 [cluster of differentiation 68], LogTLR4 [toll-like receptor 4], LogTLR5 [toll-like recep-
tor 5], two nuclear factor E2–related factor 2 (Nrf2) target genes (LogHO1 [heme oxygenase], LogNQO1 [NADH 
quinone oxidoreductase]) in each group after 12 weeks. Among the eleven genes, eight (except LogCPT-1, LogHO-1 
and LogNQO1) in the RT group (P < 0.05), nine (except LogCPT-1 and LogNQO1) in the HIAT group (P < 0.05), 
and nine (except LogHO-1 and LogNQO1) in the MICT group revealed significant changes (P < 0.05). However, 
a comparison among the groups revealed that the magnitude of the changes in all these measurements was not 
significantly different.
RT HIAT MICT
Pn = 19 n = 20 n = 13
Demographic characteristics
Age, years 51.2 ± 1.9 48.6 ± 1.8 48.2 ± 2.3 0.517
BMI, kg·m−2 27.2 ± 0.9 28.4 ± 0.9 28.8 ± 1.1 0.470
Body height, cm 172.6 ± 1.6 170.7 ± 1.0 171.2 ± 1.8 0.618
Waist circumference, cm 95.3 ± 1.2 97.1 ± 1.6 100.1 ± 4.0 0.336
Medications
Hyperglycemic, % 5.3 0 0 0.404
Hypertensive, % 26.3 30.0 0 0.138
Hyperlipidemic, % 10.5 15.0 0 0.337
Smoking, % 36.8 30.0 38.5 0.878
Cardiovascular Capacity
VO2max, ml/kg/min 29.1 ± 1.3 29.2 ± 1.2 29.1 ± 1.5 0.998
Table 2.  Baseline Characteristics of 52 Subjects with NAFLD Who were Randomly Allocated to One of 
Three 12-week Exercise Training Programs. Values are presented as the group means ± SE and as percentages. 
Abbreviations: RT, the group that performed resistance training; HIAT, the group that performed high-intensity 
interval aerobic training; MICT, the group that performed moderate-intensity continuous training; BMI, body 
mass index; VO2max, maximal oxygen consumption.
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Discussion
A need of alternative strategies with increased exercise or physical activity is strongly emphasized in the manage-
ment of NAFLD. We conducted a prospective randomized controlled study and comparatively investigated the 
effects of the differences in modality and intensity of exercise to make an appropriate proposal in the management 
of NAFLD.
The important findings of this study are as follows:
1. All three modalities of exercise, RT, HIAT, and MICT, resulted in a similar degree of improvement in the 
hepatic fat content. The modality and intensity of the exercises did not appear to be important factors.
2. Improvements in hepatic stiffness were only observed in the HIAT group. In the HIAT group, improve-
ments were also detected in the phagocytic function of Kupffer cells for foreign bodies. The intensity of 
exercise did appear to be an important factor in the improvements in hepatic fibrosis and inflammation.
3. The improvements in hepatic fat content and stiffness were not related to the reductions in weight or vis-
ceral fat. Exercise may directly benefit the pathophysiological conditions of NAFLD.
In this study, increased VO2Max, a cardiopulmonary capacity, was observed in all three groups with RT, HIAT, 
and MICT, showing the effect of 12-week training. Despite differences in the training approach, the degree of 
improvement in hepatic fat content by training of RT, HIAT, and MICT was equivalent without any significant 
difference among the three groups. The measurement in hepatic fat content was performed with the CAP on 
Transient Elastography. It has been demonstrated that the measured values of CAP are highly correlated with the 
levels of fat deposition in tissue specimens of the liver37. CAP has a high sensitivity even in patients with mild 
hepatic steatosis and is a useful diagnostic tool for NAFLD29. Based on the above, it is presumed that the modality 
and intensity of exercise do not play an important role in the improvement in hepatic fat content through exercise.
In obese subjects with NAFLD, FFAs derived from visceral adipose tissues are the major cause of hepatic fat 
synthesis38. Accordingly, it can be assumed that reducing the inflow of FFAs derived from adipose tissues into the 
liver will reduce hepatic fat accumulation in patients with NAFLD.
A decrease in the serum levels of FFAs was observed in all 3 groups, which suggests that there was a reduction 
in the inflow of FFAs into the liver. This observation may be attributed to the exercise-induced recovery of insulin 
sensitivity in the adipose tissues, which would in turn inhibit lipolysis in the tissues, leading to the reduction in 
the levels of FFAs38. These functional changes in the adipose tissues, rather than a reduction in the adipose tissue 
volume, may have been important since the measured changes in body weight and composition were very small 
(Table 3).
Moreover, in our analysis of metabolic dynamics using PBMCs, the reduced expression levels of SREBC-1c 
and ACC, a transcription factor that regulates fatty acid synthesis, was observed in all 3 groups; therefore, we 
presumed that de novo fatty acid synthesis was reduced in the liver with exercise. In contrast, no increase was 
observed in the expression levels of CPT-1 and ACO, which are involved in beta-oxidization in fatty acid degra-
dation. This finding suggests that the modality and intensity of the training regimens reduced hepatic fat accumu-
lation through modulation of fatty acid synthesis in the liver, regardless of the exercise type (Table 5).
In this study, HIAT, which is a high-intensity, low-volume, short-time exercise with lower energy consump-
tion, showed a significantly better effect on hepatic stiffness and the phagocytic function of Kupffer cells. This 
finding is notable for the management of NAFLD (Fig. 3).
Tissue diagnosis by liver biopsy is required for a definite diagnosis of NASH. However, non-invasive diag-
nostic approaches were recently developed and the benefits on diagnoses of hepatic steatosis and fibrosis on 
contrast-enhanced ultrasonography or elastography have been reported32,39. The measurement of hepatic stiffness 
RT HIAT MICT
P
n = 19 n = 20 n = 13
Baseline After Change Baseline After Change Baseline After Change
Energy Intake
TEI, kg/d−1 1983 ± 85 1868 ± 86 − 115 1929 ± 87 1905 ± 100 − 24 2041 ± 211 2061 ± 89 + 20 0.849
Carbo, g/d−1 252.1 ± 14.1 233.8 ± 12.1 − 18.3 262.5 ± 14.3 271.9 ± 15.1 + 9.4 274.9 ± 31.8 272.7 ± 11.1 − 2.2 0.734
Protein, g/d−1 79.2 ± 2.8 76.6 ± 6.9 − 2.6 70.0 ± 3.6 63.2 ± 2.1 − 6.8 68.8 ± 7.2 72.2 ± 3.2 + 3.4 0.498
Fat, g/d−1 65.2 ± 4.7 63.7 ± 4.1 − 1.5 57.9 ± 3.9 57.0 ± 3.8 − 0.9 64.1 ± 7.1 66.1 ± 4.7 + 2.0 0.934
Anthropometry
Weight, kg 82.8 ± 2.1 83.1 ± 2.0 + 0.3 83.9 ± 2.5 84.1 ± 2.6 + 0.2 85.7 ± 6.2 85.2 ± 6.3 − 0.5 0.339
Fat Mass, kg 20.3 ± 0.8 19.4 ± 0.7 − 0.9* 20.5 ± 1.0 20.1 ± 1.1 − 0.4 23.8 ± 3.2 22.8 ± 3.2 − 1.0* 0.279
Lean Mass, kg 62.5 ± 1.9 63.7 ± 1.8 + 1.2* 63.4 ± 1.5 64.0 ± 1.6 + 0.6* 61.9 ± 3.2 62.4 ± 3.2 + 0.5 0.186
VAT Area, cm−3 104.5 ± 8.3 101.9 ± 8.1 − 2.6 118.0 ± 11.5 121.2 ± 8.3 + 2.2 116.7 ± 16.9 132.7 ± 12.4 + 16.0 0.567
SAT Area, cm−3 206.8 ± 12.6 190.7 ± 8.6 − 16.1 213.5 ± 16.7 217.2 ± 12.0 + 3.7 231.7 ± 26.0 228.2 ± 26.6 − 3.5 0.359
Table 3.  Energy Intake and Anthropometry Values in 52 Subjects with NAFLD Who were Randomly 
Allocated to One of Three 12-week Exercise Training Programs. Values are presented as the group 
means ± SE. *Significant changes (P < 0.05) within group. Abbreviations: RT, resistance training; HIAT, high-
intensity aerobic training; MICT, moderate-intensity continuous training. TEI, total daily energy intake; Carbo, 
Carbohydrate VAT, visceral adipose tissue; SAT, subcutaneous adipose tissue.
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Figure 2. Changes in the levels of adipokine (A), hepatokine and myokine (B) from the baseline to the end 
point of 12 weeks in a total of 52 subjects (RT = 19, HIAT = 20 and MICT = 13) with NAFLD who were 
randomly allocated to a 12-week training program. Analysis of SEPP used ANCOVA adjusted for baseline 
values to compare changed values between groups. †P < 0.05, significant difference between the baseline and the 
12th week. IL-6, interleukin 6; TNF-α , tumor necrosis factor alpha; SEPP1, selenoprotein P; FGF-21, fibroblast 
growth factor 21; MSTN, myostatin.
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by transient elastography is considered to precisely reflect fibrosis in the liver tissue samples40,41. In addition to fibro-
sis, other factors that affect hepatic stiffness include inflammation, cholestasis, and venous pressure42. An important 
consideration in the management of NAFLD is that HIAT ameliorates fibrotic and inflammatory conditions of the 
RT HIAT MICT
P
n = 19 n = 20 n = 13
Baseline After Change Baseline After Change Baseline After Change
Liver Function test
a
LogAST, U·L−1 1.365 ± 0.022 1.381 ± 0.020 + 0.016 1.496 ± 0.048 1.476 ± 0.042 − 0.020 1.346 ± 0.034 1.332 ± 0.035 − 0.014 0.579
aALT, U·L−1 29.2 ± 2.0 25.7 ± 2.0 − 3.5 57.1 ± 11.2 50.9 ± 9.1 − 6.2 32.2 ± 5.8 26.5 ± 4.4 − 5.7* 0.215
Logγ GTP, U·L−1 1.591 ± 0.07 1.510 ± 0.05 − 0.081* 1.668 ± 0.050 1.627 ± 0.054 − 0.041* 1.566 ± 0.078 1.505 ± 0.093 − 0.061* 0.429
Insulin Resistance and Lipid Profile
a
LogFPG 1.991 ± 0.010 1.990 ± 0.015 − 0.001 2.009 ± 0.008 2.003 ± 0.013 − 0.006 1.947 ± 0.021 1.962 ± 0.006 + 0.015 0.416
aHOMA-IR 2.00 ± 0.24 1.88 ± 0.25 − 0.12 3.45 ± 0.50 3.25 ± 0.48 − 0.20 2.24 ± 0.37 2.18 ± 0.29 − 0.06 0.637
LogTriglycerides 2.042 ± 0.061 2.058 ± 0.062 + 0.016 2.116 ± 0.048 2.091 ± 0.041 − 0.025 2.179 ± 0.086 2.109 ± 0.069 − 0.070 0.326
FFAs, Eq·L−1 0.59 ± 0.05 0.45 ± 0.04 − 0.14* 0.57 ± 0.05 0.49 ± 0.04 − 0.08 0.75 ± 0.11 0.47 ± 0.04 − 0.28* 0.162
Apoptosis, Inflammation and Oxidative Stress
a
LogM30 2.143 ± 0.041 2.136 ± 0.029 − 0.007 2.518 ± 0.080 2.479 ± 0.081 − 0.039 2.177 ± 0.059 2.164 ± 0.048 − 0.013 0.755
LPS, EU·mL−1 6.41 ± 0.64 7.94 ± 0.81 + 1.53* 6.21 ± 0.63 6.80 ± 0.79 + 0.59 4.24 ± 0.78 6.11 ± 0.98 + 1.87* 0.424
Ferritin, μ g·L−1 158.7 ± 30.7 138.4 ± 26.8 − 20.3 208.5 ± 31.0 178.9 ± 26.9 − 29.6* 143.8 ± 37.1 130.2 ± 32.5 − 13.6 0.472
LogTBARS 3.750 ± 0.027 3.730 ± 0.034 − 0.020 3.808 ± 0.021 3.812 ± 0.019 + 0.004 3.799 ± 0.040 3.750 ± 0.036 − 0.049 0.289
Table 4.  The Outcomes of Liver Function Test, Apoptosis, Inflammation and Oxidative stress, Insulin 
Resistance and Lipid Profile Values in 52 Subjects with NAFLD Who were Randomly Allocated to One 
of Three 12-week Exercise Training Programs. Values are presented as the group means ± SE. *Significant 
changes (P < 0.05) within group. aANCOVA with adjustments for respective baseline values were applied to 
compare changed values between groups. Abbreviations: RT, resistance training; HIAT, high-intensity aerobic 
training; MICT, moderate-intensity continuous training; AST, aspartate aminotransferase; ALT, alanine 
aminotransferase; γ GT, gamma glutamyl transpeptidase; FPG, fasting plasma glucose; HOMA-IR, insulin 
resistance by homeostasis model; FFAs, free fatty acids; LPS, lipopolysaccharide; TBARS, thiobarbituric acid 
reactive substances.
RT (n = 19) HIAT (n = 20) MICT (n = 13)
PBaseline After Change Baseline After Change Baseline After Change
Genes Involved in Fat Synthesis
LogSREBP1c 1.549 ± 0.097 1.380 ± 0.083 − 0.169* 1.687 ± 0.095 1.450 ± 0.080 − 0.237* 1.580 ± 0.131 1.416 ± 0.111 − 0.164* 0.356
LogACC 2.123 ± 0.233 2.024 ± 0.230 − 0.099* 2.462 ± 0.245 2.319 ± 0.246 − 0.143* 2.260 ± 0.312 2.150 ± 0.309 − 0.110* 0.991
Genes Involved in Fat Degradation
LogCPT1 1.529 ± 0.093 1.384 ± 0.085 − 0.145 1.564 ± 0.090 1.432 ± 0.082 − 0.132 1.660 ± 0.124 1.442 ± 0.113 − 0.218* 0.799
LogACO 1.533 ± 0.097 1.329 ± 0.080 − 0.204* 1.586 ± 0.094 1.393 ± 0.078 − 0.193* 1.583 ± 0.130 1.417 ± 0.107 − 0.166* 0.935
Macrophage Specific Gene
LogCD11b 1.491 ± 0.108 1.210 ± 0.101 − 0.281* 1.649 ± 0.105 1.374 ± 0.099 − 0.275* 1.568 ± 0.145 1.309 ± 0.136 − 0.259* 0.964
LogCD14 1.670 ± 0.090 1.447 ± 0.090 − 0.223* 1.761 ± 0.087 1.534 ± 0.087 − 0.227* 1.696 ± 0.121 1.520 ± 0.120 − 0.176* 0.516
LogCD68 1.578 ± 0.091 1.467 ± 0.090 − 0.111* 1.685 ± 0.088 1.565 ± 0.088 − 0.120* 1.630 ± 0.122 1.518 ± 0.121 − 0.112* 0.969
LogTLR4 1.407 ± 0.091 1.199 ± 0.073 − 0.208* 1.438 ± 0.089 1.259 ± 0.072 − 0.179* 1.420 ± 0.123 1.239 ± 0.099 − 0.181* 0.941
Nrf2 Target Gene
LogHO1 2.085 ± 0.031 2.095 ± 0.040 + 0.010 2.082 ± 0.033 2.143 ± 0.046 + 0.061* 2.141 ± 0.035 2.140 ± 0.046 − 0.001 0.855
LogNQO1 2.027 ± 0.044 1.977 ± 0.048 − 0.050 1.953 ± 0.039 1.910 ± 0.044 − 0.043 1.947 ± 0.047 1.952 ± 0.052 + 0.005 0.643
Table 5.  Expression Levels of Fat Metabolism-related Genes, Macrophage Specific Genes and Nrf2 Target 
Genes in PBMC for 52 Subjects with NAFLD Who were Randomly Allocated to One of Three 12-week 
Exercise Training Programs. Values are presented as the group means ± standard error. *Significant changes 
(P < 0.05) within group. Abbreviations: PBMC, peripheral blood mononuclear cell; RT, resistance training; 
HIAT, high-intensity aerobic training; MICT, moderate-intensity continuous training; SREBP1c, sterol 
regulatory element-binding protein 1c; ACC, acetyl-CoA carboxylase; CPT1, carnitine palmitoyltransferase I; 
ACO, acyl CoA oxidase; CD, cluster of differentiation; TLR, toll-like receptor; Nrf2, nuclear factor E2–related 
factor 2; HO1, heme oxygenase; NQO1, NADH quinone oxidoreductase.
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liver. Although improvements in hepatic fat accumulation due to exercise have been reported in many studies of 
NAFLD5,6, there have been few studies that examined improvements in hepatic fibrosis and inflammation43,44.
Research has determined that the phagocytic activity of Kupffer cells is reduced in the livers of nonalco-
holic steatohepatitis (NASH) patients45,46. Rencently, it has been revealed that Sonazoid, an intravenous 
contrast-enhanced agent for ultrasonography, is phagocytized by Kupffer cells and that phagocytic activity of 
Kupffer cells is reduced in NASH45. Reduced uptake of contrast-enhanced agent into the liver is observed in the 
early stage of NASH46. In our study, the luminance level of the Kupffer cell-phase was remarkably reduced in 
moderately to severely obese subjects with suspicious liver fibrosis (Findings submitted elsewhere for publica-
tion). It is likely that HIAT restored the impaired Kupffer cells’ phagocytic function, which in turn improved the 
hepatic inflammation and fibrogenesis associated with NAFLD.
In the HIAT group, the levels of ferritin, an inflammatory marker (Table 4), and the levels of leptin, an adi-
pokine that induces inflammatory reactions and hepatic fibrosis, were significantly reduced (Fig. 2) after the 
Figure 3. Changes in the levels of hepatic steatosis (A) and markers associated with liver fibrosis (B) from 
the baseline to the end point of 12 weeks in a total of 52 subjects (RT = 19, HIAT = 20 and MICT = 13) with 
NAFLD who were randomly allocated to a 12-week training program. †P < 0.05, significant difference between 
baseline and 12th week; brackets *P < 0.05, significant difference among the three program groups. NAFLD-FS, 
non-alcoholic fatty liver disease fibrosis score; WFA+ -M2BP, wisteria floribunda agglutinin-positive human 
Mac-2-binding protein.
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training. Gene expressions of inflammatory mediators TLR4, TLR5, CD11b, and CD14 were reduced in the 
PBMCs. These results were consistent with previous studies47,48 that have demonstrated that exercise exerts 
anti-inflammatory effects through the decreased expression of TLR4. Our results revealed a further increase 
in serum LPS concentrations induced by the exercise training. This suggests an increased flux of LPS from the 
intestines. It is likely that in the obese subjects in the HIAT group, the decreased TLR4/CD14 expression contrib-
uted to the attenuation of LPS-induced inflammatory reactions in the liver. In addition, the restored phagocytic 
function of Kupffer cells for foreign bodies likely contributed to the further attenuation.
Another possible explanation for the improvement in the inflammation was Nrf2 activation induced by the 
high-intensity exercise49. Recently, researchers have reported that Nrf2 restrains macrophage inflammatory 
response through opposing transcriptional upregulation of the proinflammatory cytokine gene50. HIAT con-
siderably increased the expression level of HO-1, which is known to be a prototypical Nrf2 target gene (Table 5). 
Collectively, the changes in the expression levels of these molecules induced by HIAT would be expected to 
improve in vivo inflammatory conditions in obese men and lead to improvements in hepatic stiffness.
The findings of Kistler et al. support our observations. Kistler et al.43 conducted an investigation of the rela-
tionship between the intensity of exercise and the histological severity of NAFLD. Their results revealed that 
high-intensity physical activity was closely connected with reduced adjusted odds of morbidity due to NASH. 
They concluded that the intensity of exercise was an important factor in the improvements in hepatic inflamma-
tion and fibrosis.
This study has the strength of being a prospective randomized controlled study. Obese adult men with NAFLD 
were randomly allocated to one of three groups (RT, HIAT, and MICT group). The exercise training was con-
ducted under the supervision of experts, and state-of-the-art techniques for the assessment of features were used 
as the analytical methods. On the other hand, this research is limited in that no sedentary control group was set. 
No liver biopsy was performed because of ethical issues, and no histological evaluation on steatosis and fibrosis 
was made. In particular, the correlation between exercise training and the pathological conditions of the liver 
tissues (inflammation and fibrosis) was not revealed. Finally, our study design did not consider sampling size 
calculation to estimate the effect of sample size. Therefore, the small sample size might have limited the statistical 
power of the study.
In summary, the results of a prospective randomized controlled study suggest that 12-week exercise regimens 
of RT, HIAT, and MICT all improved hepatic fat accumulation, independent of reduction of weight or visceral 
fat. HIAT also appeared to improve hepatic stiffness, and thus this modality could be recommended for NAFLD 
subjects with suspected fibrosis. It should be noted that exercise was beneficial for the management of NAFLD 
even when conducted without concomitant dietary therapy. In the future, it will be necessary to further clarify the 
role of exercise training in the management of NAFLD in a large-scale clinical study.
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